The Gastrointestinal Tumor drugs in development market research report provides comprehensive information on the therapeutics under development for Gastrointestinal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Gastrointestinal Tumor. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Gastrointestinal Tumor and features dormant and discontinued products.

GlobalData tracks 61 drugs in development for Gastrointestinal Tumor by 54 companies/universities/institutes. The top development phase for Gastrointestinal Tumor is preclinical with 20 drugs in that stage. The Gastrointestinal Tumor pipeline has 57 drugs in development by companies and four by universities/ institutes. Some of the companies in the Gastrointestinal Tumor pipeline products market are: Systimmune, FutureGen Biopharm Technology and Elicio Therapeutics.

The key targets in the Gastrointestinal Tumor pipeline products market include Claudin 18, Cellular Tumor Antigen p53, and CD3.

The key mechanisms of action in the Gastrointestinal Tumor pipeline product include CD3 Agonist with three drugs in Phase II. The Gastrointestinal Tumor pipeline products include ten routes of administration with the top ROA being Oral and ten key molecule types in the Gastrointestinal Tumor pipeline products market including Small Molecule, and Monoclonal Antibody.

Gastrointestinal Tumor overview

Gastrointestinal (GI) tumors refer to abnormal growths or neoplasms that develop in various parts of the digestive system, which includes the esophagus, stomach, intestines (small and large), liver, gallbladder, and pancreas. These tumors can be benign (non-cancerous) or malignant (cancerous).

For a complete picture of Gastrointestinal Tumor’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.